Abstract
The efficacy, safety and usefulness of grepafloxacin (GPFX) for patients with acute infectious enteritis, and the carriers mainly of bacillary dysentery, were investigated. The drug was administered at a daily dose of 200 mg once a day for 3 days to patients with cholera, 7 days to patients with Salmonella enteritis and 5 days to patients with other conditions of infectious enteritis including dysentery.
1. The global clinical efficacy was analyzed in 77 of the 113 patients who received administration.
2. The drug was markedly effective or effective for symptoms in 39 patients, and the rate of efficacy was 100%.
3. Bacteriologically, the drug was effective for dysentery bacillus in 41 (97.6%) of 42, Salmonella in 7 of 9, Campylobacter in 5 of 9 and enteropathogenic Escherichia coli in 9 of 9.
4. The global clinical efficacy for 72 cases (excluding 4 cases: 1 with bacillary dysentery, 2 with Salmonella enteritis and 1 with Campylobacter enteritis) was 94.8%(72/76).
5. None of the patients (n=112) had side effects. Abnormal findings were observed in 8 (8%) of the patients (n 100) on laboratory tests. Elevations of s-GOT and s-GPT were the main findings, but they were mild.
6. As to usefulness, 52.6% of the patients (n=78) were very satisfied, and 89.7% were satisfied or very satisfied.
7. The influence of GPFX administration on fecal level and intestinal bacterial flora was investigated in one patient with bacterium-negative enteritis. Results approximately equivalentto those in healthy subjects were obtained.
The above results suggest that GPFX is highly useful for infectious enteritis conditions such as bacillary dysentery.
